Although patients with FLT3-ITD mutations tend to have a shorter overall and relapse-free survival compared with patients without the mutation [20], the mutant-to-wild-type allelic ratio, insertion site, ITD length, karyotype, and the simultaneous presence of a mutation in the NPM1 gene were reported to influence the prognostic utility of FLT3-ITD in AML patients [20,21]. The gene discussed is NPM1; the disease is acute myeloid leukemia.